Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFER | P55789 | 1/20 | 0.78 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.62 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.62 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.62 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | P62805 | 1/20 | 0.59 |
| ▸ | EP300 | Q09472 | 1/20 | 0.59 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | MMP3 | P08254 | 1/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.57 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9281809 | 0.89 | GFER (0.76) | GFERNR4A1NR4A2NR4A3SLC16A3 | |
| SCHEMBL1954449 | 0.88 | GFER (0.80) | GFERNR4A1NR4A2NR4A3SLC16A3 | |
| SCHEMBL1310079 | 0.87 | GFER (0.78) | GFERNR4A1NR4A2NR4A3SLC16A3 | |
| SCHEMBL1307732 | 0.86 | GFER (0.76) | GFERNR4A1NR4A2NR4A3SLC16A3 | |
| SCHEMBL5475049 | 0.86 | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 (0.74) | GFERNR4A1NR4A2NR4A3SLC16A3 | |
| SCHEMBL1308632 | 0.86 | GRIK1 (0.72) | GFERSLC16A3KDM4EALDH1A1HSD17B10 | |
| SCHEMBL14413339 | 0.86 | GFER (0.76) | GFERNR4A1NR4A2NR4A3SLC16A3 | |
| SCHEMBL1308410 | 0.86 | GFER (0.76) | GFERSLC16A3KDM4EALDH1A1HSD17B10 | |
| SCHEMBL21275460 | 0.83 | RAB9A (0.76) | GFERSLC16A3KDM4EH4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16EP300 | |
| SCHEMBL6350942 | 0.82 | GFER (0.70) | GFERNR4A1NR4A2NR4A3SLC16A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2332529-A1 | Substituted aromatic diamines as ligands of vesicular glutamate transporter 1 and 2 (vGLUT1 and vGLUT2) | Grünenthal GmbH (DE) | 2011-06-15 | — | — | EP | claimed |
| US-8183236-B2 | Compounds with HIV-1 integrase inhibitory activity and use thereof as anti-HIV/AIDS therapeutics | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2012-05-22 | — | — | US | disclosed |
| US-8183236-B2 | Compounds with HIV-1 integrase inhibitory activity and use thereof as anti-HIV/AIDS therapeutics | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2012-05-22 | — | — | US | disclosed |
| EP-2332529-A1 | Substituted aromatic diamines as ligands of vesicular glutamate transporter 1 and 2 (vGLUT1 and vGLUT2) | Grünenthal GmbH (DE) | 2011-06-15 | — | — | EP | disclosed |
| US-20090088420-A1 | COMPOUNDS WITH HIV-1 INTEGRASE INHIBITORY ACTIVITY AND USE THEREOF AS ANTI-HIV/AIDS THERAPEUTICS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2009-04-02 | — | — | US | disclosed |
| US-20090088420-A1 | COMPOUNDS WITH HIV-1 INTEGRASE INHIBITORY ACTIVITY AND USE THEREOF AS ANTI-HIV/AIDS THERAPEUTICS | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2009-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088420-A1 | COMPOUNDS WITH HIV-1 INTEGRASE INHIBITORY ACTIVITY AND USE THEREOF AS ANTI-HIV/AIDS THERAPEUTICS | TYMP, IMPDH1, SAMHD1 | GFER 3067/4885NR4A1 1599/4885NR4A2 2830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.